回复：EUSOMA和NCCN应将新辅助治疗后的临床分期作为指导治疗的质量指标。

{"title":"回复：EUSOMA和NCCN应将新辅助治疗后的临床分期作为指导治疗的质量指标。","authors":"Giuseppe Catanuto, Damiano Gentile, Federica Martorana, Giuseppe Curigliano, Isabel Rubio","doi":"10.1016/j.ejso.2025.110130","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":11522,"journal":{"name":"Ejso","volume":" ","pages":"110130"},"PeriodicalIF":3.5000,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Reply to: EUSOMA and NCCN should include clinical staging after neoadjuvant therapy as a quality indicator for treatment guidance.\",\"authors\":\"Giuseppe Catanuto, Damiano Gentile, Federica Martorana, Giuseppe Curigliano, Isabel Rubio\",\"doi\":\"10.1016/j.ejso.2025.110130\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":11522,\"journal\":{\"name\":\"Ejso\",\"volume\":\" \",\"pages\":\"110130\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2025-05-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ejso\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.ejso.2025.110130\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ejso","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ejso.2025.110130","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}